Unequivocal randomized trial data show that PSA velocity does not benefit decision making in localized prostate cancer. A recent paper suggests that the literature is wrong and that PSA velocity does predict aggressive disease; however, the study design is flawed and the key claim seems to be based on a typographical error.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wolters, T., Roobol, M. J., Bangma, C. H. & Schroder, F. H. Is Prostate-Specific Antigen Velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur. Urol. 55, 385–392 (2009).
Thompson, I. M. et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 98, 529–534 (2006).
Fall, K. et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J. Natl Cancer Inst. 99, 526–532 (2007).
Pinsky, P. F. et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 109, 1689–1695 (2007).
Andriole, G. L. et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J. Urol. 185, 126–131 (2011).
Ross, A. E. et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 28, 2810–2816 (2010).
Ulmert, D. et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J. Clin. Oncol. 26, 835–841 (2008).
Vickers, A. J., Savage, C., O'Brien, M. F. & Lilja, H. A systematic review of pretreatment PSA velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 27, 398–403 (2009).
Wallner, L. P. et al. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU lnt. doi: 10.1111/j.1464-410X.2012.11651.x.
Vickers, A. J. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J. Natl Cancer Inst. 103, 1635–1636 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Vickers, A. Why is PSA velocity such a sticky concept?. Nat Rev Urol 10, 189–190 (2013). https://doi.org/10.1038/nrurol.2013.47
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.47
